193 related articles for article (PubMed ID: 36272973)
21. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
22. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
23. Desmoplasia in Lymph Node Metastasis of Pancreatic Adenocarcinoma Reveals Activation of Cancer-Associated Fibroblasts Pattern and T-helper 2 Immune Cell Infiltration.
Nizri E; Bar-David S; Aizic A; Sternbach N; Lahat G; Wolf I; Klausner J
Pancreas; 2019 Mar; 48(3):367-373. PubMed ID: 30768574
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
25. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
Zins K; Kovatchki D; Lucas T; Abraham D
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
[TBL] [Abstract][Full Text] [Related]
26. The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.
Kung PJ; Lai TY; Cao J; Hsu LC; Chiang TC; Ou-Yang P; Tsai CY; Tsai YF; Lin CW; Chen CC; Tsai MK; Tien YW; Lee CY
Cancer Immunol Immunother; 2022 Mar; 71(3):705-718. PubMed ID: 34374812
[TBL] [Abstract][Full Text] [Related]
27. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
[TBL] [Abstract][Full Text] [Related]
28. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.
Tsukamoto M; Imai K; Ishimoto T; Komohara Y; Yamashita YI; Nakagawa S; Umezaki N; Yamao T; Kitano Y; Miyata T; Arima K; Okabe H; Baba Y; Chikamoto A; Ishiko T; Hirota M; Baba H
Cancer Sci; 2019 Jan; 110(1):310-320. PubMed ID: 30426611
[TBL] [Abstract][Full Text] [Related]
30. Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cancer-associated/Normal Fibroblasts.
Novák Š; Kolář M; Szabó A; Vernerová Z; Lacina L; Strnad H; Šáchová J; Hradilová M; Havránek J; Španko M; Čoma M; Urban L; Kaňuchová M; Melegová N; Gürlich R; Dvořák J; Smetana K; Gál P; Szabo P
Cancer Genomics Proteomics; 2021; 18(3):221-243. PubMed ID: 33893076
[TBL] [Abstract][Full Text] [Related]
31. Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma.
Sabbaghian MS; Rothberger G; Alongi AP; Gagner JP; Goldberg JD; Rolnitzky L; Chiriboga L; Hajdu CH; Zagzag D; Basch R; Shamamian P
Anticancer Res; 2010 Jul; 30(7):2911-7. PubMed ID: 20683032
[TBL] [Abstract][Full Text] [Related]
32. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors.
Djurec M; Graña O; Lee A; Troulé K; Espinet E; Cabras L; Navas C; Blasco MT; Martín-Díaz L; Burdiel M; Li J; Liu Z; Vallespinós M; Sanchez-Bueno F; Sprick MR; Trumpp A; Sainz B; Al-Shahrour F; Rabadan R; Guerra C; Barbacid M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1147-E1156. PubMed ID: 29351990
[TBL] [Abstract][Full Text] [Related]
33. Tumor necrosis factor-α regulates angiogenesis of BeWo cells via synergy of PlGF/VEGFR1 and VEGF-A/VEGFR2 axes.
Tanaka K; Watanabe M; Tanigaki S; Iwashita M; Kobayashi Y
Placenta; 2018 Dec; 74():20-27. PubMed ID: 30591201
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
35. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.
Elyada E; Bolisetty M; Laise P; Flynn WF; Courtois ET; Burkhart RA; Teinor JA; Belleau P; Biffi G; Lucito MS; Sivajothi S; Armstrong TD; Engle DD; Yu KH; Hao Y; Wolfgang CL; Park Y; Preall J; Jaffee EM; Califano A; Robson P; Tuveson DA
Cancer Discov; 2019 Aug; 9(8):1102-1123. PubMed ID: 31197017
[TBL] [Abstract][Full Text] [Related]
36. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4
Gorchs L; Fernández Moro C; Bankhead P; Kern KP; Sadeak I; Meng Q; Rangelova E; Kaipe H
Front Immunol; 2019; 10():847. PubMed ID: 31068935
[TBL] [Abstract][Full Text] [Related]
37. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
38. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population.
Maehira H; Miyake T; Iida H; Tokuda A; Mori H; Yasukawa D; Mukaisho KI; Shimizu T; Tani M
Ann Surg Oncol; 2019 Dec; 26(13):4791-4804. PubMed ID: 31583548
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer.
Huang H; Brekken RA
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C233-C243. PubMed ID: 32432930
[TBL] [Abstract][Full Text] [Related]
40. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
